ΔINK4 T2D risk region hiPSC
General Donor Information
Phenotype and Disease related information (Donor)
|No disease was diagnosed.
|Disease associated phenotypes
|Is the medical history available upon request?
|Is clinical information available?
|Has the donor karyotype been analysed?
Other Genotyping (Donor)
|Is there genome-wide genotyping or functional data available?
|Other cell lines of this donor
External Databases (Donor)
Also have a look at the ethics information for the parental line HMGUi001-A .
|Is there an MTA available for the cell line?
|For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
|The targeting vector was generated at IDR, and contained the PU6-(BbsI) sgRNA_CAG-Cas9-GFP-bpA plasmid, Addgene ID86985.
|Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above?
|Constraints for use or distribution
|According to donor consent the line must not be used for commercial purposes. For research purposes project specific review by an Ethics Committee is oblgatory.
The source cell information can be found in the parental cell line HMGUi001-A.
|Passage number reprogrammed
|HMGUi001-A-1 was targeted with PU6-(BbsI) sgRNA_CAG-Cas9-GFP-bpA plasmid, Addgene ID8698,5 to make a large deletion at the INK4 locus. This vector expresses Cas9 enzyme and sgRNAs.
Vector free reprogramming
|Selection criteria for clones
|FACS sorting of GFP expressing cells, genomic DNA exctraction from GFP+ single cell clones, screening for the 8kb deletion by conventional PCR with FA-RB and FC-RC primer pairs, identification of wild type and biallelic clones for the large deletion by a 1910 bp wild type-specific PCR product and a 750 bp deletion-specific PCR product, confirmation of the precise deletion of the target region by Sanger sequencing of the PCR products
|Derived under xeno-free conditions
|Derived under GMP?
|Available as clinical grade?
Base medium: StemMACS iPS-Brew XF medium
Main protein source: xeno-fee
Serum concentration: 0 %
|Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
|Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
|Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Analysis of Undifferentiated Cells
StemMACS Trilineage Differentiation plus immunostaining
Microbiology / Virus Screening
Karyotyping (Cell Line)
|Has the cell line karyotype been analysed?
Karyotyping method: G-Banding
Other Genotyping (Cell Line)
|Genetic modifications not related to a disease